Categories
Change Password!
Reset Password!
Early sacubitril/valsartan use leads to greater left ventricular recovery and fewer emergency visits in newly diagnosed HFrEF patients.
A new multi-institutional study from Taiwan highlights the clinical benefits of early initiation of sacubitril/valsartan therapy in patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF). The findings suggest that commencing treatment within 6 months of diagnosis remarkably improves heart function and minimizes emergency department (ED) visits, when compared to delayed initiation.
Researchers analyzed data from 410 patients diagnosed with HFrEF. Volunteers were segregated into two groups: early users (188 patients) who began sacubitril/valsartan within 6 months of diagnosis, and late users (222 patients) who started treatment after 6 months. Patient characteristics, clinical outcomes, and alteration in left ventricular ejection fraction (LVEF) were compared utilizing inverse probability of treatment weighting to balance baseline differences.
Although both groups experienced improvements in LVEF — a key marker of cardiac function — the early treatment group showed a markedly greater increase, from an average of 28.7% to 45.3%, versus 28.9% to 40.1% in the late treatment group. Importantly, early users also had a 16% lower risk of cumulative ED visits (hazard ratio [HR]: 0.84). While no prominent differences were observed in all-cause death, cardiovascular death, or heart failure hospitalization between the two groups, these results underline the potential of early sacubitril/valsartan initiation to enhance functional recovery and minimize urgent care utilization.
The authors conclude that the early introduction of sacubitril/valsartan in newly diagnosed HFrEF patients may yield superior benefits in terms of cardiac remodeling and healthcare burden, reinforcing the requisition for prompt and proactive care strategies in this population.
Acta Cardiologica Sinica
Clinical Impact of the Early Use of Sacubitril/Valsartan in Newly Diagnosed Heart Failure and Reduced Ejection Fraction
Tzyy-Jer Hsu et al.
Comments (0)